Castle Biosciences - CSTL Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $37.88
  • Forecasted Upside: 13.77%
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$33.29
▼ -0.02 (-0.06%)

This chart shows the closing price for CSTL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Castle Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CSTL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CSTL

Analyst Price Target is $37.88
▲ +13.77% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Castle Biosciences in the last 3 months. The average price target is $37.88, with a high forecast of $44.00 and a low forecast of $25.00. The average price target represents a 13.77% upside from the last price of $33.29.

This chart shows the closing price for CSTL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 8 contributing investment analysts is to buy stock in Castle Biosciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/20/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/18/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/16/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/14/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/14/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/12/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/11/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/10/2024

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/6/2024ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$37.00 ➝ $44.00
11/5/2024Lake Street CapitalBoost TargetBuy ➝ Buy$34.00 ➝ $40.00
11/5/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$37.00 ➝ $39.00
11/5/2024KeyCorpBoost TargetOverweight ➝ Overweight$28.00 ➝ $36.00
10/29/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$35.00 ➝ $42.00
10/14/2024BTIG ResearchBoost TargetBuy ➝ Buy$35.00 ➝ $40.00
8/6/2024StephensReiterated RatingOverweight ➝ Overweight$37.00 ➝ $37.00
8/6/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$34.00 ➝ $37.00
7/5/2024Robert W. BairdReiterated RatingOutperform ➝ Outperform$34.00 ➝ $34.00
5/3/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$33.00 ➝ $34.00
3/1/2024KeyCorpBoost TargetOverweight ➝ Overweight$25.00 ➝ $28.00
3/1/2024ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$33.00 ➝ $37.00
12/14/2023GuggenheimInitiated CoverageBuy$25.00
8/4/2023KeyCorpLower TargetOverweight ➝ Overweight$37.00 ➝ $25.00
8/3/2023Robert W. BairdBoost Target$25.00 ➝ $30.00
6/15/2023BTIG ResearchLower Target$38.00 ➝ $30.00
6/7/2023ScotiabankLower Target$54.00 ➝ $33.00
6/5/2023SVB SecuritiesLower Target$50.00 ➝ $35.00
6/5/2023Lake Street CapitalLower Target$41.00 ➝ $32.00
6/5/2023Robert W. BairdLower Target$35.00 ➝ $25.00
5/4/2023Robert W. BairdLower Target$38.00 ➝ $35.00
3/2/2023StephensReiterated RatingOverweight$41.00
3/1/2023Lake Street CapitalLower Target$63.00 ➝ $41.00
3/1/2023Robert W. BairdLower TargetOutperform$42.00 ➝ $38.00
1/4/2023ScotiabankInitiated CoverageSector Outperform$54.00
11/3/2022Robert W. BairdLower TargetOutperform$48.00 ➝ $41.00
8/15/2022BTIG ResearchBoost Target$47.00
8/9/2022Robert W. BairdBoost TargetOutperform$44.00 ➝ $48.00
8/9/2022Leerink PartnersBoost TargetMarket Outperform$45.00 ➝ $50.00
5/10/2022Canaccord Genuity GroupLower Target$80.00 ➝ $65.00
5/10/2022Robert W. BairdLower Target$50.00 ➝ $44.00
4/5/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$94.00 ➝ $80.00
3/1/2022Lake Street CapitalLower Target$94.00 ➝ $63.00
3/1/2022Robert W. BairdLower Target$82.00 ➝ $60.00
1/7/2022StephensInitiated CoverageOverweight$59.00
11/9/2021Leerink PartnersLower TargetOutperform$85.00 ➝ $75.00
11/9/2021Robert W. BairdBoost TargetOutperform$78.00 ➝ $82.00
8/10/2021Robert W. BairdBoost TargetOutperform$73.00 ➝ $78.00
7/14/2021Leerink PartnersBoost TargetOutperform$80.00 ➝ $85.00
5/13/2021Robert W. BairdReiterated RatingBuy$73.00
4/30/2021Lake Street CapitalInitiated CoverageBuy$94.00
3/9/2021Robert W. BairdLower TargetOutperform$87.00 ➝ $82.00
2/3/2021KeyCorpBoost TargetOverweight$70.00 ➝ $90.00
1/15/2021Leerink PartnersBoost TargetOutperform$70.00 ➝ $80.00
12/17/2020BTIG ResearchBoost TargetBuy$60.00 ➝ $80.00
12/11/2020Leerink PartnersBoost TargetOutperform$57.00 ➝ $70.00
11/9/2020KeyCorpInitiated CoverageOverweight$70.00
9/25/2020Leerink PartnersBoost TargetOutperform$50.00 ➝ $57.00
8/11/2020Leerink PartnersBoost TargetOutperform$45.00 ➝ $50.00
5/12/2020Leerink PartnersBoost TargetOutperform$40.00 ➝ $45.00
3/27/2020Robert W. BairdLower TargetOutperform$38.00 ➝ $35.00
3/11/2020BTIG ResearchBoost Target$32.00 ➝ $41.00
3/11/2020Leerink PartnersBoost TargetOutperform$35.00 ➝ $40.00
3/11/2020Robert W. BairdBoost TargetOutperform$37.00 ➝ $38.00
(Data available from 11/10/2019 forward)

News Sentiment Rating

0.61 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 15 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/14/2024
  • 7 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/14/2024
  • 5 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/13/2024
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/13/2024
  • 13 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
8/12/2024
  • 8 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/11/2024
  • 10 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/11/2024
  • 15 very positive mentions
  • 26 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
11/10/2024

Current Sentiment

  • 15 very positive mentions
  • 26 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Castle Biosciences logo
Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Read More

Today's Range

Now: $33.29
Low: $32.62
High: $33.87

50 Day Range

MA: $30.92
Low: $27.86
High: $34.67

52 Week Range

Now: $33.29
Low: $16.20
High: $35.84

Volume

396,272 shs

Average Volume

501,296 shs

Market Capitalization

$932.35 million

P/E Ratio

166.46

Dividend Yield

N/A

Beta

0.99

Frequently Asked Questions

What sell-side analysts currently cover shares of Castle Biosciences?

The following Wall Street analysts have issued reports on Castle Biosciences in the last twelve months: BTIG Research, Canaccord Genuity Group Inc., Guggenheim, KeyCorp, Lake Street Capital, Robert W. Baird, Scotiabank, and Stephens.
View the latest analyst ratings for CSTL.

What is the current price target for Castle Biosciences?

0 Wall Street analysts have set twelve-month price targets for Castle Biosciences in the last year. Their average twelve-month price target is $37.88, suggesting a possible upside of 13.8%. Scotiabank has the highest price target set, predicting CSTL will reach $44.00 in the next twelve months. Guggenheim has the lowest price target set, forecasting a price of $25.00 for Castle Biosciences in the next year.
View the latest price targets for CSTL.

What is the current consensus analyst rating for Castle Biosciences?

Castle Biosciences currently has 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CSTL will outperform the market and that investors should add to their positions of Castle Biosciences.
View the latest ratings for CSTL.

What other companies compete with Castle Biosciences?

How do I contact Castle Biosciences' investor relations team?

Castle Biosciences' physical mailing address is 820 S FRIENDSWOOD DRIVE SUITE 201, FRIENDSWOOD TX, 77546. The company's listed phone number is (866) 788-9007 and its investor relations email address is [email protected]. The official website for Castle Biosciences is castlebiosciences.com. Learn More about contacing Castle Biosciences investor relations.